Clinical Trial Detail

NCT ID NCT04197986
Title Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors QED Therapeutics, Inc.
Indications

invasive bladder transitional cell carcinoma

Therapies

Infigratinib

Age Groups: adult senior

Additional content available in CKB BOOST